A US Medicaid program to test centralized contracting for sickle cell disease gene therapies has attracted widespread interest from state payors.
Key Takeaways
-
States are interested in a CMS program on centralized contracting for gene therapies treating sickle cell disease.
-
Rep. Brett Guthrie is concerned the program will not let states work together to negotiate prices
The US Center for Medicare and Medicaid Innovation has received letters of intent from “a majority of states that represent about 80% of patients with sickle cell disease,” CMMI Director Elizabeth Fowler said at a recent House Energy and Commerce/Health Subcommittee hearing
